IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.

MLA

Nakayama, Yoichi, et al. “IL-6 Inhibitors and JAK Inhibitors as Favourable Treatment Options for Patients with Anaemia and Rheumatoid Arthritis: ANSWER Cohort Study.” Rheumatology (Oxford, England), vol. 63, no. 2, Feb. 2024, pp. 349–57. EBSCOhost, https://doi.org/10.1093/rheumatology/kead299.

APA

Nakayama, Y., Watanabe, R., Yamamoto, W., Ebina, K., Hirano, T., Kotani, T., Shiba, H., Katayama, M., Son, Y., Amuro, H., Onishi, A., Jinno, S., Hara, R., Murakami, K., Murata, K., Ito, H., Tanaka, M., Matsuda, S., Morinobu, A., & Hashimoto, M. (2024). IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Rheumatology (Oxford, England), 63(2), 349–357. https://doi.org/10.1093/rheumatology/kead299

Chicago

Nakayama, Yoichi, Ryu Watanabe, Wataru Yamamoto, Kosuke Ebina, Toru Hirano, Takuya Kotani, Hideyuki Shiba, et al. 2024. “IL-6 Inhibitors and JAK Inhibitors as Favourable Treatment Options for Patients with Anaemia and Rheumatoid Arthritis: ANSWER Cohort Study.” Rheumatology (Oxford, England) 63 (2): 349–57. doi:10.1093/rheumatology/kead299.